靶向GPC3的CAR-T细胞可清除小鼠原位肝细胞癌
研究比较了基于人源化YP7(hYP7)和HN3抗体的GPC3靶向CAR-T细胞功能,发现CAR(hYP7)T细胞在66%小鼠中3周内清除肿瘤,而CAR(HN3)T细胞无效。CAR(hYP7)T细胞诱导穿孔素和颗粒酶介导的凋亡并降低β-catenin活性,且持续扩增并形成多能亚群。
要点
- CAR(hYP7)T细胞在66%小鼠中3周内消除肿瘤,CAR(HN3)T细胞未减少肿瘤负荷。
- CAR(hYP7)T细胞诱导穿孔素和颗粒酶介导的凋亡并降低HCC细胞活性β-catenin水平。
- CAR(hYP7)T细胞在肿瘤微环境和脾中持续存在至7周,并发生抗原诱导选择。
核心结论
- CAR(hYP7)T细胞可清除GPC3阳性HCC细胞,可能通过诱导穿孔素和颗粒酶介导的凋亡或降低Wnt信号实现。
研究设计与样本
- 使用健康供者和HCC患者外周血单核细胞制备基于hYP7和HN3抗体的CAR-T细胞。
- NSG小鼠分别接受腹腔注射表达荧光素酶的Hep3B或HepG2细胞形成异种移植瘤,或肝脏注射形成原位瘤。
- 小鼠接受盐水、未转导T细胞(mock对照)、CAR(HN3)T细胞、CAR(hYP7)T细胞或CD19 CAR-T细胞(对照)注射。
- 采用微滴数字PCR和基因组测序分析小鼠体内持久存在的CAR-T细胞。
主要发现
- 注射CAR(hYP7)T细胞后3周内66%小鼠肿瘤消除,而CAR(HN3)T细胞未减少肿瘤负荷。
- 接受CAR(hYP7)T细胞的小鼠在再次挑战Hep3B细胞后仍无肿瘤。
- CAR(hYP7)T细胞诱导穿孔素和颗粒酶介导的凋亡并降低HCC细胞活性β-catenin水平。
- CAR(hYP7)T细胞在肿瘤微环境和脾中持续扩增并形成多能亚群至7周。
- CAR(hYP7)T细胞输注后5周和7周分别有3.9%和18.1%检测到NUPL1整合,而CAR(HN3)或CD19 CAR-T细胞无共同整合位点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Glypican 3 (GPC3) is an oncofetal antigen involved in Wnt-dependent cell proliferation that is highly expressed in hepatocellular carcinoma (HCC). We investigated whether the functions of chimeric antigen receptors (CARs) that target GPC3 are affected by their antibody-binding properties. METHODS: We collected peripheral blood mononuclear cells from healthy donors and patients with HCC and used them to create CAR T cells, based on the humanized YP7 (hYP7) and HN3 antibodies, which have high affinities for the C-lobe and N-lobe of GPC3, respectively. NOD/SCID/IL-2Rgcnull (NSG) mice were given intraperitoneal injections of luciferase-expressing (Luc) Hep3B or HepG2 cells and after xenograft tumors formed, mice were given injections of saline or untransduced T cells (mock control), or CAR (HN3) T cells or CAR (hYP7) T cells. In other NOD/SCID/IL-2Rgcnull (NSG) mice, HepG2-Luc or Hep3B-Luc cells were injected into liver, and after orthotopic tumors formed, mice were given 1 injection of CAR (hYP7) T cells or CD19 CAR T cells (control). We developed droplet digital polymerase chain reaction and genome sequencing methods to analyze persistent CAR T cells in mice. RESULTS: Injections of CAR (hYP7) T cells eliminated tumors in 66% of mice by week 3, whereas CAR (HN3) T cells did not reduce tumor burden. Mice given CAR (hYP7) T cells remained tumor free after re-challenge with additional Hep3B cells. The CAR T cells induced perforin- and granzyme-mediated apoptosis and reduced levels of active β-catenin in HCC cells. Mice injected with CAR (hYP7) T cells had persistent expansion of T cells and subsets of polyfunctional CAR T cells via antigen-induced selection. These T cells were observed in the tumor microenvironment and spleen for up to 7 weeks after CAR T-cell administration. Integration sites in pre-infusion CAR (HN3) and CAR (hYP7) T cells were randomly distributed, whereas integration into NUPL1 was detected in 3.9% of CAR (hYP7) T cells 5 weeks after injection into tumor-bearing mice and 18.1% of CAR (hYP7) T cells at week 7. There was no common site of integration in CAR (HN3) or CD19 CAR T cells from tumor-bearing mice. CONCLUSIONS: In mice with xenograft or orthoptic liver tumors, CAR (hYP7) T cells eliminate GPC3-positive HCC cells, possibly by inducing perforin- and granzyme-mediated apoptosis or reducing Wnt signaling in tumor cells. GPC3-targeted CAR T cells might be developed for treatment of patients with HCC.
引用
- Li D, Li N, Zhang YF, et al. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Gastroenterology. 2020. PMID: 32060001. doi:10.1053/j.gastro.2020.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。